N. P. Bochkov Research Centre for Medical Genetics, Moscow, Russia.
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, Moscow, Russia.
Bull Exp Biol Med. 2022 Apr;172(6):738-742. doi: 10.1007/s10517-022-05468-5. Epub 2022 May 2.
The detection of genes related to the lifetime of patients with clear cell renal cancer provides information on the mechanisms of the tumor development and can be the basis for creating approaches to predict patient survival. In this paper, the expression of genes regulated by the HIF2α transcriptional factor was studied. Based on the results obtained here and previously identified genes regulated by the transcriptional factor HIF1α, a new panel of 6 genes, including the BAP1 gene, was proposed. Expression of genes of this panel allows predicting the survival of patients with clear cell renal cancer with high sensitivity (93%), specificity (96%), and relative risk (21.5). After verification, the application of this panel can be useful for personalized treatment of patients with clear cell renal cancer, which will increase the effectiveness of therapy.
检测与透明细胞肾细胞癌患者生存期相关的基因可提供有关肿瘤发展机制的信息，并且可以作为预测患者生存的方法的基础。在本文中，研究了受 HIF2α 转录因子调节的基因的表达。基于此处获得的结果和先前鉴定的受转录因子 HIF1α 调节的基因，提出了一个新的 6 个基因的基因表达谱，包括 BAP1 基因。该基因表达谱可用于预测透明细胞肾细胞癌患者的生存情况，具有高灵敏度（93%）、特异性（96%）和相对风险（21.5）。经过验证，该基因表达谱的应用对于透明细胞肾细胞癌患者的个体化治疗是有用的，这将提高治疗的效果。
